Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Healthcare Biotechnology
Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.


TSX:MSCL - Post by User

Satellos Bioscience Inc > .12 next leg
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Comment by SuperMoneyon Nov 28, 2019 9:31am
49 Views
Post# 30401457

RE:.12 next leg

RE:.12 next legJuansito, how are you doing here? Any thoughts about any drivers that could make ICO moving?

juansito wrote: Incoming at ico019 NR.
 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities